Your browser doesn't support javascript.
loading
The role of asymptomatic screening in the detection of recurrent ovarian cancer.
Richardson, M T; Routson, S; Karam, A; Dorigo, O; Levy, K; Renz, M; Diver, E J.
Afiliación
  • Richardson MT; Stanford Women's Cancer Center, Stanford Cancer Institute, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA, USA.
  • Routson S; Stanford Women's Cancer Center, Stanford Cancer Institute, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA, USA.
  • Karam A; Stanford Women's Cancer Center, Stanford Cancer Institute, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA, USA.
  • Dorigo O; Stanford Women's Cancer Center, Stanford Cancer Institute, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA, USA.
  • Levy K; Stanford Women's Cancer Center, Stanford Cancer Institute, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA, USA.
  • Renz M; Stanford Women's Cancer Center, Stanford Cancer Institute, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA, USA.
  • Diver EJ; Stanford Women's Cancer Center, Stanford Cancer Institute, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Gynecol Oncol Rep ; 33: 100595, 2020 Aug.
Article en En | MEDLINE | ID: mdl-32548232
OBJECTIVE: To investigate the utility of asymptomatic screening, including CA-125, imaging, and pelvic exam, in the diagnosis and management of recurrent ovarian cancer. METHODS: Women with ovarian cancer whose cancer recurred after remission were categorized by first method that their provider suspected disease recurrence: CA-125, imaging, symptoms, or physical exam. Differences in clinicopathologic, primary treatment characteristics, and outcomes data including secondary cytoreductive surgery (SCS) outcome and overall survival (OS) were collected. RESULTS: 102 patients were identified at our institution from 2003 to 2015. 20 recurrences were detected by symptoms, while 62 recurrences were diagnosed first by asymptomatic rise in CA-125, 5 by pelvic exam, and 15 by imaging in the absence of known exam abnormality or rise in CA-125.Mean time to recurrence was 18.9 months, and median survival was 45.8 months. These did not vary by recurrence detection method (all p > 0.4). Patients whose disease was detected by CA-125 were less likely to undergo SCS than those detected by other means (21.7% vs. 35.0%, p = 0.007). In addition to the 5 patients whose recurrence was detected primarily by pelvic exam, an additional 10 (total n = 15) patients had an abnormal pelvic exam at time of diagnosis of recurrence. DISCUSSION: Recurrence detection method was not associated with differing rates of survival or optimal SCS, however those patients detected by CA-125 were less likely to undergo SCS. The pelvic exam was a useful tool for detecting a significant proportion of recurrences.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Idioma: En Revista: Gynecol Oncol Rep Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Idioma: En Revista: Gynecol Oncol Rep Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos